How to appeal a UnitedHealthcare multiple myeloma (non-car-t) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for multiple myeloma (non-car-t)

Cited policy: OptumRx Tecvayli (Teclistamab-cqyv) for Relapsed/Refractory MM PA

Adult RRMM. ≥4 prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Hematologist-oncologist Rx. REMS-enrolled site (CRS / ICANS monitoring). Step-up dosing inpatient or REMS-monitored outpatient. Tocilizumab access on-site. Reauth at 4 cycles with ≥PR per IMWG Kumar 2016.

How UnitedHealthcare denies multiple myeloma (non-car-t) — and how to counter it

Where UnitedHealthcare pushes back: 1) Bispecifics experimental / non-formulary; 2) Must trial CAR-T first; 3) ≥5 prior lines required by plan; 4) Outpatient step-up not authorized.

Counter-arguments that hold up: Tecvayli FDA-approved Oct 25, 2022 (accelerated) at ≥4 prior lines per FDA label — NOT 5. NCCN MM v3.2024 category-2A for triple-class-refractory disease. MajesTEC-1 (Moreau NEJM 2022;387:495-505) ORR 63%, median DOR 18.4 mo. CAR-T (Abecma / Carvykti) is a separately-considered option, not a prerequisite — manufacturing slot 4-8 wk wait, apheresis, lymphodepletion required; rapid progression often precludes. Aug 2023 label adds biweekly dosing after ≥4 cycles + ≥PR.

What UnitedHealthcare typically denies for multiple myeloma (non-car-t)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For multiple myeloma (non-car-t), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the multiple myeloma (non-car-t) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Darzalex IV
• Darzalex Faspro SC
• Sarclisa
• Tecvayli
• Elrexfio
• Talvey

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.